Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Semler to Report Second Quarter and First Half 2018 Financial Results and Host Conference Call on July 31, 2018

Semler Scientific,Inc.
Posted on: 23 Jul 18
Semler to Report Second Quarter and First Half 2018 Financial Results and Host Conference Call on July 31, 2018

PR Newswire

SAN JOSE, Calif., July 23, 2018

SAN JOSE, Calif., July 23, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report second quarter and first half 2018 financial results before the open of U.S. financial markets on Tuesday, July 31, 2018. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 11 a.m. ET the same day.

The conference call may be accessed by dialing (877) 359-9508 for domestic callers and (224) 357-2393 for international callers. Please specify to the operator that you would like to join the "Semler Second Quarter and First Half 2018 Financial Results Call, conference ID#: 5790429." The conference call will be archived on Semler's website at www.semlerscientific.com.

About Semler Scientific, Inc.:

Semler Scientific, Inc. is an emerging growth company that provides technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers. Its mission is to develop, manufacture and market innovative proprietary products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific's first patented and U.S. Food and Drug Administration, or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. In March 2015, Semler Scientific received FDA 510(k) clearance for the next generation version of this product named QuantaFlo™, which was commercially launched in August 2015 to more comprehensively evaluate its customers' patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at www.semlerscientific.com.

 

CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
212 966 3650

View original content:http://www.prnewswire.com/news-releases/semler-to-report-second-quarter-and-first-half-2018-financial-results-and-host-conference-call-on-july-31-2018-300684547.html

SOURCE Semler Scientific, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 23/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.